Recurrent glioblastoma
Conditions
Interventions
The "TMZ+ABX" combined treatment group:"TMZ+ABX" combined treatment
Sponsors
Southern Medical University Southern Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Voluntarily sign the informed consent form; 2.Age: 18 to 70 years old, gender not limited; 3.Patients diagnosed with recurrent glioblastoma (WHO Grade IV) in accordance with the 2016 World Health Organization (WHO) glioma Diagnostic Guidelines, the 2022 National Health Commission Glioma Diagnosis and Treatment Guidelines of China, etc. 4.Preoperative KPS score >=60 points; 5.The standard for blood routine examination should meet the following requirements: ANC >=1.5×109/L; PLT >=90×109/L; Hb >=90g/L; 6.Biochemical tests must meet the following standards: TBIL=50 mL/min (CockcroftGault formula); 7.The coagulation test standards should comply with: International normalized ratio (INR) or prothrombin time (PT) =55%); 9.The Fridericia method corrected QT interval (QTcF) for electrocardiogram in females was less than 470 ms;
Exclusion criteria
Exclusion criteria: 1.Patients who are unable to undergo cranial MRI examinations; 2.Pregnant and lactating women; 3.Patients who were found to have active bleeding through cranial CT or MRI examination before enrollment; 4.A history of malignant tumors in other systems within the past 5 years; 5.Suffering from severe cardiovascular and respiratory system diseases; 6.Patients who, as determined by the researcher, are not suitable to participate in this trial; 7.There is a grade 3 or higher chronic toxic reaction according to the National Cancer Institute's Common Adverse Event Evaluation Criteria (NCI-CTCAE5.0);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival time;Objective response rate; | — |
Countries
China
Contacts
Public ContactGuo-zhong Yi
Southern Medical University Southern Hospital
Outcome results
None listed